Synthetic phosphopeptides enable quantitation of the content and function of the four phosphorylation states of phospholamban in cardiac muscle

Journal of Biological Chemistry

Volumn 289, Issue 42, 2014, Pages 29397-29405

  Ablorh, Naa Adjeley D ^a   Dong, Xiaoqiong ^a   James, Zachary M ^a   Xiong, Qiang ^a   Zhang, Jianyi ^a   Thomas, David D ^a   Karim, Christine B ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; DISEASE CONTROL; HEART; PHOSPHOLIPIDS; TISSUE;

ATP-ASE ACTIVITY; CARDIAC MUSCLES; DIFFERENTIAL EFFECT; LEFT VENTRICULAR HYPERTROPHIES; PHOSPHOLIPID MEMBRANE; PLB PHOSPHORYLATION; SARCOPLASMIC RETICULUM; SYNTHETIC PEPTIDE;

PHOSPHORYLATION;

ADENOSINE TRIPHOSPHATASE (CALCIUM); PHOSPHOLAMBAN; PHOSPHOPEPTIDE; PROTEIN 2P PLB; PROTEIN P16 PLB; PROTEIN P17 PLB; PROTEIN U PLB; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATASE; CALCIUM; CALCIUM BINDING PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CYCLIC AMP DEPENDENT PROTEIN KINASE;

ANIMAL TISSUE; ARTICLE; CALCIUM METABOLISM; CONCENTRATION (PARAMETERS); ENZYME ACTIVITY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; IMMUNOBLOTTING; NONHUMAN; PHOSPHOLIPID MEMBRANE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SHAM PROCEDURE; TISSUE HOMOGENATE; ANIMAL; CHEMISTRY; DISEASE MODEL; HEART FAILURE; METABOLISM; PHOSPHORYLATION; SWINE;

ADENOSINE TRIPHOSPHATASES; ANIMALS; CALCIUM; CALCIUM-BINDING PROTEINS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; HEART FAILURE; MYOCARDIUM; PHOSPHOPEPTIDES; PHOSPHORYLATION; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SWINE;

EID: 84908032882     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.556621     Document Type: Article

References (69)

1. Bers, D. M. (2002) Cardiac excitation-contraction coupling. Nature 415, 198-205
2. Simmerman, H. K., and Jones, L. R. (1998) Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol. Rev. 78, 921-947
3. 2+-ATPase. Biochemistry 47, 3-13
4. Akin, B. L., Hurley, T. D., Chen, Z., and Jones, L. R. (2013) The structural basis for phospholamban inhibition of the calcium pump in sarcoplasmic reticulum. J. Biol. Chem. 288, 30181-30191
5. Marks, A. R. (2013) Calcium cycling proteins and heart failure: mechanisms and therapeutics. J. Clin. Invest. 123, 46-52
6. Pattison, J. S., Waggoner, J. R., James, J., Martin, L., Gulick, J., Osinska, H., Klevitsky, R., Kranias, E. G., and Robbins, J. (2008) Phospholamban overexpression in transgenic rabbits. Transgenic Res. 17, 157-170
7. Simmerman, H. K., Collins, J. H., Theibert, J. L., Wegener, A. D., and Jones, L. R. (1986) Sequence analysis of phospholamban: identification of phosphorylation sites and two major structural domains. J. Biol. Chem. 261, 13333-13341
8. Colyer, J., and Wang, J. H. (1991) Dependence of cardiac sarcoplasmic reticulum calcium pump activity on the phosphorylation status of phospholamban. J. Biol. Chem. 266, 17486-17493
9. 2+-ATPase 2a (SERCA2a) protein binding interactions in human cardiac sarcoplasmic reticulum vesicles using chemical cross-linking. J. Biol. Chem. 287, 7582-7593
10. 2+-ATPase activity and left ventricular function in STZ-induced diabetic rats. Biomed. Environ. Sci. 26, 577-583
11. Li, J., Bigelow, D. J., and Squier, T. C. (2003) Phosphorylation by cAMP-dependent protein kinase modulates the structural coupling between the transmembrane and cytosolic domains of phospholamban. Biochemistry 42, 10674-10682
12. James, Z. M., McCaffrey, J. E., Torgersen, K. D., Karim, C. B., and Thomas, D. D. (2012) Protein-protein interactions in calcium transport regulation probed by saturation transfer electron paramagnetic resonance. Biophys. J. 103, 1370-1378
13. Karim, C. B., Zhang, Z., Howard, E. C, Torgersen, K. D., and Thomas, D. D. (2006) Phosphorylation-dependent conformational switch in spinlabeled phospholamban bound to SERCA. J. Mol. Biol. 358, 1032-1040
14. Dong, X., and Thomas, D. D. (2014) Time-resolved FRET reveals the structural mechanism of SERCA-PLB regulation. Biochem. Biophys. Res. Commun. 449, 196-201
15. Steenaart, N. A., Ganim, J. R., Di Salvo, J., and Kranias, E. G. (1992) The phospholamban phosphatase associated with cardiac sarcoplasmic reticulum is a type 1 enzyme. Arch. Biochem. Biophys. 293, 17-24
16. MacDougall, L. K., Jones, L. R., and Cohen, P. (1991) Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospholamban. Eur. J. Biochem. 196, 725-734
17. Jakab, G., and Kranias, E. G. (1988) Phosphorylation and dephosphorylation of purified phospholamban and associated phosphatidylinositides. Biochemistry 27, 3799-3806
18. Colyer, J. (1998) Phosphorylation states of phospholamban. Ann. NY. Acad. Sci. 853, 79-91
19. 2+ loading preceded by a hypercontractile state and diastolic failure in the α (1C) TG mouse. PLoS One 4, e4133
20. Said, M., Becerra, R., Valverde, C. A., Kaetzel, M. A., Dedman, J. R., Mundina-Weilenmann, C, Wehrens, X. H., Vittone, L., and Mattiazzi, A. (2011) Calcium-calmodulin dependent protein kinase II (CaMKII): a main signal responsible for early reperfusion arrhythmias. J. Mol. Cell Cardiol. 51, 936-944
21. 2+ load. Heart Rhythm 8, 784-787
22. Schmidt, A. G., Edes, I., and Kranias, E. G. (2001) Phospholamban: a promising therapeutic target in heart failure?, Cardiovasc. Drugs Ther. 15, 387-396
23. Miyamoto, S. D., Stauffer, B. L., Nakano, S., Sobus, R., Nunley, K., Nelson, P., and Sucharov, C. C. (2014) β-Adrenergic adaptation in paediatric idiopathic dilated cardiomyopathy. Eur. Heart J. 35, 33-41
24. 2+-handling in failing human myocardium. J. Mol. Cell Cardiol. 33, 1345-1353
25. Gruber, S. J., Haydon, S., and Thomas, D. D. (2012) Phospholamban mutants compete with wild type for SERCA binding in living cells. Biochem. Biophys. Res. Commun. 420, 236-240
26. Cornea, R. L., Gruber, S. J., Lockamy, E. L., Muretta, J. M., Jin, D., Chen, J., Dahl, R., Bartfai, T., Zsebo, K. M., Gillispie, G. D., and Thomas, D. D. (2013) High-throughput FRET assay yields allosteric SERCA activators. J. Biomol. Screen. 18, 97-107
27. Lockamy, E. L., Cornea, R. L., Karim, C. B., and Thomas, D. D. (2011) Functional and physical competition between phospholamban and its mutants provides insight into the molecular mechanism of gene therapy for heart failure. Biochem. Biophys. Res. Commun. 408, 388-392
28. Oh, J. G., Kim, J., Jang, S. P., Nguen, M., Yang, D. K., Jeong, D., Park, Z. Y., Park, S. G., Hajjar, R. J., and Park, W. J. (2013) Decoy peptides targeted to protein phosphatase 1 inhibit dephosphorylation of phospholamban in cardiomyocytes. J. Mol. Cell. Cardiol. 56, 63-71
29. 2+ current in pressure overload heart failure. J. Biol. Chem. 283, 25524-25532
30. Ablorh, N. A., Miller, T., Nitu, F., Gruber, S. J., Karim, C, and Thomas, D. D. (2012) Accurate quantitation of phospholamban phosphorylation by immunoblot. Anal. Biochem. 425, 68-75
31. 2+ and contraction following/3-adrenergic stimulation of rat heart. Pflugers Arch. 436, 948-956
32. Calaghan, S., White, E., and Colyer, J. (1998) Preservation of the in vivo phosphorylation status of phospholamban in the heart: evidence for a site-specific difference in the dephosphorylation of phospholamban, Biochem. Biophys. Res. Commun. 248, 701-705
33. Calaghan, S., Kozera, L., and White, E. (2008) Compartmentalisation of cAMP-dependent signalling by caveolae in the adult cardiac myocyte. J. Mol. Cell. Cardiol. 45, 88-92
34. Grote-Wessels, S., Baba, H. A., Boknik, P., El-Armouche, A., Fabritz, L., Gillmann, H. J., Kucerova, D., Matus, M., Müller, F. U., Neumann, J., Schmitz, M., Stümpel, F., Theilmeier, G., Wohlschlaeger, J., Schmitz, W., and Kirchhefer, U. (2008) Inhibition of protein phosphatase 1 by inhibitor-2 exacerbates progression of cardiac failure in a model with pressure overload. Cardiovasc. Res. 79, 464-471
35. 2+ homeostasis differentially determine the progression of cTnT-related cardiomyopathies in murine models. Am. J. Physiol. Heart Circ. Physiol. 297, H614-H626
36. 2+-pump stimulation. Biochem. J. 316, 201-207
37. Loyer, X., Gomez, A. M., Milliez, P., Fernandez-Velasco, M., Vangheluwe, P., Vinet, L., Charue, D., Vaudin, E., Zhang, W., Sainte-Marie, Y., Robidel, E., Marty, I., Mayer, B., Jaisser, F., Mercadier, J. J., Richard, S., Shah, A. M., Benitah, J. P., Samuel, J. L., and Heymes, C. (2008) Cardiomyocyte overexpression of neuronal nitric oxide synthase delays transition toward heart failure in response to pressure overload by preserving calcium cycling. Circulation 117, 3187-3198
38. Tada, M., Inui, M., Yamada, M., Kadoma, M., Kuzuya, T., Abe, H., and Kakiuchi, S. (1983) Effects of phospholamban phosphorylation catalyzed by adenosine 3':5'-monophosphate- and calmodulin-dependent protein kinases on calcium transport ATPase of cardiac sarcoplasmic reticulum. J. Mol. Cell. Cardiol. 15, 335-346
39. Raeymaekers, L., Hofmann, F., and Casteels, R. (1988) Cyclic GMP-dependent protein kinase phosphorylates phospholamban in isolated sarcoplasmic reticulum from cardiac and smooth muscle. Biochem. J. 252, 269-273
40. Karim, C. B., Zhang, Z., and Thomas, D. D. (2007) Synthesis of TOAC spin-labeled proteins and reconstitution in lipid membranes. Nat. Protoc. 2, 42-49
41. Karim, C. B., Kirby, T. L., Zhang, Z., Nesmelov, Y., and Thomas, D. D. (2004) Phospholamban structural dynamics in lipid bilayers probed by a spin label rigidly coupled to the peptide backbone. Proc. Natl. Acad. Sci. U. S. A. 101, 14437-14442
42. Mueller, B., Karim, C. B., Negrashov, I. V., Kutchai, H, and Thomas, D. D. (2004) Direct detection of phospholamban and sarcoplasmic reticulum Ca-ATPase interaction in membranes using fluorescence resonance energy transfer. Biochemistry 43, 8754-8765
43. Stokes, D. L., and Green, N. M. (1990) Three-dimensional crystals of CaATPase from sarcoplasmic reticulum: symmetry and molecular packing. Biophys. J. 57, 1-14
44. Ji, Y., Loukianov, E., Loukianova, T., Jones, L. R., and Periasamy, M. (1999) SERCA1a can functionally substitute for SERCA2a in the heart. Am. J. Physiol. 276, H89-H97
45. Gong, G., Liu, J., Liang, P., Guo, T., Hu, Q., Ochiai, K., Hou, M., Ye, Y., Wu, X., Mansoor, A., From, A. H., Ugurbil, K., Bache, R. J., and Zhang, J. (2003) Oxidative capacity in failing hearts. Am. J. Physiol. Heart Circ. Physiol. 285, H541-H548
46. Wang, X., Hu, Q., Mansoor, A., Lee, J., Wang, Z., Lee, T., From, A. H., and Zhang, J. (2006) Bioenergetic and functional consequences of stem cellbased VEGF delivery in pressure-overloaded swine hearts. Am. J. Physiol. Heart Circ. Physiol. 290, H1393-H1405
47. Towbin, H., Staehelin, T., and Gordon, J. (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. U. S. A. 76, 4350-4354
48. Karim, C. B., Marquardt, C. G., Stamm, J. D., Barany, G., and Thomas, D. D. (2000) Synthetic null-cysteine phospholamban analogue and the corresponding transmembrane domain inhibit the Ca-ATPase. Biochemistry 39, 10892-10897
49. Karim, C. B., Paterlini, M. G., Reddy, L. G., Hunter, G. W., Barany, G., and Thomas, D. D. (2001) Role of cysteine residues in structural stability and function of a transmembrane helix bundle. J. Biol. Chem. 276, 38814-38819
50. Lockwood, N. A., Tu, R. S., Zhang, Z., Tirrell, M. V., Thomas, D. D., and Karim, C. B. (2003) Structure and function of integral membrane protein domains resolved by peptide-amphiphiles: application to phospholamban. Biopolymers 69, 283-292
51. Reddy, L. G., Cornea, R. L., Winters, D. L., McKenna, E., and Thomas, D. D. (2003) Defining the molecular components of calcium transport regulation in a reconstituted membrane system. Biochemistry 42, 4585-4592
52. Li, J., James, Z. M., Dong, X., Karim, C. B., and Thomas, D. D. (2012) Structural and functional dynamics of an integral membrane protein complex modulated by lipid headgroup charge. J. Mol. Biol. 418, 379-389
53. Sande, J. B., Sjaastad, I., Hoen, I. B., Bøkenes, J., Tønnessen, T., Holt, E., Lunde, P. K., and Christensen, G. (2002) Reduced level of serine (16) phosphorylated phospholamban in the failing rat myocardium: a major contributor to reduced SERCA2 activity. Cardiovasc. Res. 53, 382-391
54. 2+-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. J. Mol. Cell. Cardiol. 31, 479-491
55. Mishra, S., Sabbah, H. N., Jain, J. C., and Gupta, R. C. (2003) Reduced Ca2+-calmodulin-dependent protein kinase activity and expression in LV myocardium of dogs with heart failure. Am. J. Physiol. Heart Circ. Physiol. 284, H876-H883
56. 2+/calmodulin-dependent protein kinase is altered in heart failure. Circ. Res. 86, 596-605
57. Huang, B., Wang, S., Qin, D., Boutjdir, M., and El-Sherif, N. (1999) Diminished basal phosphorylation level of phospholamban in the postinfarction remodeled rat ventricle: role of β-adrenergic pathway, G (i) protein, phosphodiesterase, and phosphatases. Circ. Res. 85, 848-855
58. Boateng, S., Seymour, A. M., Dunn, M., Yacoub, M., and Boheler, K. (1997) Inhibition of endogenous cardiac phosphatase activity and measurement of sarcoplasmic reticulum calcium uptake: a possible role of phospholamban phosphorylation in the hypertrophied myocardium, Biochem. Biophys. Res. Commun. 239, 701-705
59. 2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins. Circ. Cardiovasc. Genet. 7, 132-143
60. Periasamy, M., and Huke, S. (2001) SERCA pump level is a critical determinant of Ca2+ homeostasis and cardiac contractility. J. Mol. Cell. Cardiol. 33, 1053-1063
61. Ardehali, H, Kasper, E. K., and Baughman, K. L. (2005) Diagnostic approach to the patient with cardiomyopathy: whom to biopsy. Am. Heart J. 149, 7-12
62. Cooper, L. T., Baughman, K. L., Feldman, A. M., Frustaci, A., Jessup, M., Kuhl, U., Levine, G. N., Narula, J., Starling, R. C, Towbin, J., and Virmani, R. (2007) The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Eur. Heart J. 28, 3076-3093
63. Chimenti, C, and Frustaci, A. (2013) Contribution and risks of left ventricular endomyocardial biopsy in patients with cardiomyopathies: a retrospective study over a 28-year period. Circulation 128, 1531-1541
64. Zhao, W., Frank, K. F., Chu, G., Gerst, M. J., Schmidt, A. G., Ji, Y., Periasamy, M., and Kranias, E. G. (2003) Combined phospholamban ablation and SERCA1a overexpression result in a new hyperdynamic cardiac state. Cardiovasc. Res. 57, 71-81
65. 2+ ATPase as a therapeutic target for heart failure. Exp. Opin. Biol. Ther. 10, 29-41
66. Hoshijima, M., Ikeda, Y., Iwanaga, Y., Minamisawa, S., Date, M. O., Gu, Y., Iwatate, M., Li, M., Wang, L., Wilson, J. M., Wang, Y., Ross, J., Jr., and Chien, K. R. (2002) Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat. Med. 8, 864-871
67. Hoshijima, M. (2005) Gene therapy targeted at calcium handling as an approach to the treatment of heart failure. Pharmacol. Ther. 105, 211-228
68. Bers, D. M. (2010) CaMKII inhibition in heart failure makes jump to human. Circ. Res. 107, 1044-1046
69. 2+/calmodulin-dependent protein kinase II improves contractility in human failing myocardium. Circ. Res. 107, 1150-1161